Anne Wojcicki on embracing gatekeepers, not fighting them

Executive overview

Most founders see gatekeepers as obstacles to push past. Anne Wojcicki learned that the smartest path is collaboration. When 23andMe hit a wall with the FDA, she stopped chasing workarounds and committed to working with regulators instead of around them. This shift from fight to partnership gave her first-mover advantage and paved the way for the entire genetic testing industry.

Gatekeepers can open doors, not just block them—if you cultivate the relationship.

From skeptic to believer

Anne's career began in healthcare investing, where she grew disillusioned by how the system exploited sick people. She wanted to empower patients to access their own genetic information directly, bypassing the traditional doctor-gatekeeper model. This mission became 23andMe.

• Started with investor background in hospitals and healthcare systems
• Witnessed how gatekeeping (doctors, institutions) controlled patient information
• Drew inspiration from HIV community advocacy and emerging social networks

Building the weird-to-wonderful bridge

23andMe launched to crickets. Most people didn't understand why they'd want genetic testing. The science was sound, but the market didn't see the point.

• 2007 launch: 1,000 kits sold, then dropped to 10–20 per day
• Core problem: consumers were unaware they had a problem to solve
• Ancestry became the killer feature—people wanted to discover relatives, not discuss disease

This oblique approach (ancestry as gateway to health) became essential because it:

• Made the concept accessible and emotionally engaging
• Created viral loop (people sharing discoveries with family)
• Bought time to educate consumers on the health applications

Running into the FDA

By 2013, 23andMe had momentum. Time Magazine named them Invention of the Year in 2008. Then the FDA sent a cease-and-desist letter, claiming genetic tests were medical devices requiring approval.

Anne's first instinct: find a legal workaround based on First Amendment free speech arguments. A wise regulator asked a simple question: "Do you want to sell this in two years, or do you want to change healthcare?"

• Multiple state-level cease-and-desist letters preceded the FDA action
• Anne had built relationships with regulators through prior run-ins
• The FDA wasn't a bug to exploit; it was a threshold she'd eventually need to cross

Choosing collaboration over disruption

Anne chose the slow, hard path: work with the FDA, prove safety and efficacy, and accept years of delay.

• Provided extensive validation data to prove safety and consumer comprehension
• Built regulatory pathway where none existed
• Established trust through transparency and rigor

This approach created a moat:

• Other companies now had clearer regulatory path
• FDA gained confidence in the category
• Consumers trusted the approval process

The paradox: slowing down to scale up. By submitting to the regulator instead of fighting, Anne ensured 23andMe would move faster long-term than any competitor trying to skirt the system.

Lessons on gatekeepers

Gatekeepers come in three forms:

1. The Indiana Jones approach: shoot through them with force or legal weapons
2. The Jurassic Park approach: find an ingenious workaround or hack
3. The Holy Grail approach: answer honestly and work through them

Most founders default to Jones or Grail. Wojcicki discovered that sometimes the most disruptive path is the third—working directly with the gatekeeper.

• Knowing the right people in gatekeeping organizations matters enormously (Spotify founder Daniel Ek learned this with the music industry)
• Regulators are not enemies; they see the full landscape and hold keys to legitimacy
• First-mover advantage belongs to whoever builds regulatory trust, not whoever hacks fastest

The healthcare vision ahead

With FDA partnership established, 23andMe can now focus on the real frontier: what to do with the information once people have it.

• Risk discovery (e.g., type 2 diabetes predisposition) is growing faster than consumer knowledge
• Healthcare will increasingly shift from doctor-centric to phone-centric, data-driven model
• 23andMe positioned to lead because it earned regulatory credibility first